Core Viewpoint - Boqii Holding Limited will terminate its Deposit Agreement and implement a reverse stock split, consolidating every 160 ordinary shares into one new ordinary share, with plans to list its Class A ordinary shares on NYSE American LLC [1][2] Company Actions - The termination of the Deposit Agreement was approved by shareholders on June 26, 2025 [1] - A reverse stock split will occur, consolidating every 160 ordinary shares into one new ordinary share [1] - The company plans to list its Class A ordinary shares on NYSE American LLC, replacing the American depositary shares (ADSs) [2] Company Overview - Boqii Holding Limited is a leading pet-focused platform in China, offering a wide selection of high-quality pet products [3] - The company provides products from global leading brands, local emerging brands, and its own private labels, including Yoken, Mocare, and D-cat [3] - Boqii's online sales platforms include Boqii Mall and flagship stores on third-party e-commerce platforms, enhancing customer access and shopping experience [3]

Supreme Court limits courts' ability to issue nationwide injunctions, backing President Trump's efforts to prevent judges from blocking his agendahttps://t.co/8pjqUDkzmC ...

Core Insights - Carnival's international operations are crucial for assessing its financial strength and growth potential [1][2] - The company's total revenue for the quarter was $6.33 billion, a 9.5% increase year-over-year [4] International Revenue Trends - Australia contributed $315 million, or 4.98% of total revenue, which was an 11.19% miss against expectations of $354.7 million [5] - Other International markets generated $275 million, accounting for 4.35% of total revenue, exceeding the estimate of $212.65 million by 29.32% [6] - Europe represented 31.04% of total revenue, translating to $1.96 billion, surpassing expectations by 4.11% [7] Revenue Forecasts - For the current fiscal quarter, total revenue is projected at $8 billion, a 1.3% increase year-over-year, with contributions expected from Australia (6.3%), Other International (3.6%), and Europe (30%) [8] - For the full year, total revenue is anticipated to reach $26.37 billion, reflecting a 5.4% increase, with regional contributions from Australia (6.4%), Other International (4%), and Europe (29.3%) [9] Market Performance - Carnival's stock has increased by 13% over the past month, outperforming the S&P 500's 6% increase [13] - Over the past three months, the company's shares rose by 51.5%, compared to a 7.9% increase in the S&P 500 [13]

Core Insights - Yerbaé Brands Corp. has successfully completed a business combination with Safety Shot, Inc., where Safety Shot acquired all outstanding shares of Yerbaé [1][2] - The transaction was executed through a court-approved plan of arrangement, resulting in Safety Shot shareholders owning approximately 81.64% of the combined company, while former Yerbaé shareholders own about 18.36% [2][3] Transaction Overview - Under the arrangement agreement dated January 7, 2025, Safety Shot acquired all Yerbaé shares, with each Yerbaé shareholder receiving 0.2918 of a Safety Shot share for each Yerbaé share held [3] - The total number of Safety Shot shares issued in the transaction was 19,881,948 [2] - Yerbaé shares will be delisted from the TSX Venture Exchange and OTCQX effective June 30, 2025 [3] Shareholder Information - Yerbaé shareholders with physical share certificates must submit a Letter of Transmittal to receive their Safety Shot shares [4] - For shareholders holding shares in book-entry form or brokerage accounts, the exchange of shares is automatic [5] Company Profiles - Safety Shot, Inc. specializes in wellness and dietary supplements, notably developing Sure Shot, a patented product that lowers blood alcohol content while enhancing clarity and energy [6] - Yerbaé Brands Corp. produces plant-based energy beverages that are zero calorie, zero sugar, and cater to various dietary preferences, aiming to disrupt the energy beverage market [7] Advisory Information - Maxim Group LLC acted as the exclusive financial advisor to Safety Shot during the merger [8] - Legal counsel for Yerbaé was provided by Cozen O'Connor LLP, while Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as legal counsel for Safety Shot [9]

Indonesian President Prabowo Subianto is set to attend the BRICS summit next month in Brazil https://t.co/txrCH8kNyX ...

Eleven former executives of companies linked to Miteni are sentenced to a combined 141 years in prison by an Italian court for one of the largest groundwater contaminations of forever chemicals in Europe https://t.co/EGnHrdwcE8 ...

Core Insights - Equinox Gold Corp. (EQX) has a robust financial position with significant cash flows, supporting its development projects and liquidity [1][6] - The Greenstone mine is a key asset, expected to produce approximately 390,000 ounces of gold annually at full capacity [2][6] - The company plans to pursue deleveraging in the second half of 2025, leveraging strong cash flow generation [1][6] Financial Position - EQX ended Q1 with $173 million in unrestricted cash and $65 million in an undrawn credit facility, indicating strong liquidity [1][6] - B2Gold Corp. (BTG) reported cash and cash equivalents of $330 million and $800 million available for future drawdowns under its credit facility [3] - Eldorado Gold Corporation (EGO) had $978 million in cash and $241 million in available credit, totaling around $1.2 billion in liquidity [4] Production and Growth - The ramp-up at the Greenstone mine is currently underway, targeting an annual production of 390,000 ounces of gold [2][6] - The recent business combination with Calibre Mining Corp. is expected to enhance production growth and cash flow for EQX [2] Valuation and Market Performance - EQX is trading at a forward 12-month earnings multiple of 7.83, which is about 40.5% lower than the industry average of 13.17 [8] - The Zacks Consensus Estimate indicates a year-over-year earnings rise of 135% for 2025 and 123.4% for 2026, although EPS estimates have been trending down recently [9]

MONTCLAIR, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- 180 Degree Capital Corp. (NASDAQ:TURN) (“180 Degree Capital”) today provides notice to its shareholders that the date of the previously announced special meeting of shareholders for the sole purpose of electing directors (“Director Election Special Meeting”) has been moved to September 15, 2025. This change of date resulted from constructive conversations with the shareholders who submitted a demand request on June 17, 2025 (the “Demand Letter”), who acknow ...

Core Insights - Ultragenyx Pharmaceutical Inc. has received Breakthrough Therapy Designation from the FDA for GTX-102 as a treatment for Angelman syndrome [1][2] - The designation highlights the urgent need for effective treatments and the promising clinical results observed with GTX-102 [2] - The Phase 3 Aspire study is currently enrolling participants, with plans for an additional Aurora study to evaluate GTX-102 in other genotypes and ages expected to start later in 2025 [3] Company Overview - Ultragenyx is a biopharmaceutical company focused on developing therapies for serious rare and ultra-rare genetic diseases [7] - The company has a diverse portfolio of approved medicines and treatment candidates aimed at addressing high unmet medical needs [7] - Ultragenyx's management team has extensive experience in the development and commercialization of rare disease therapeutics [8] Product Information - GTX-102 (apazunersen) is an investigational antisense oligonucleotide therapy designed to reactivate expression of the UBE3A gene [4] - The therapy has received multiple designations from the FDA, including Orphan Drug Designation and Fast Track Designation [4] - The Phase 1/2 study demonstrated consistent developmental gains in 74 patients aged 4-17 with a full maternal UBE3A gene deletion [2] Angelman Syndrome Insights - Angelman syndrome is a rare neurogenetic disorder affecting approximately 60,000 people in commercially accessible geographies [5] - The disorder is characterized by cognitive impairment, motor impairment, and seizures, requiring continuous care for affected individuals [6] - There are currently no approved therapies for Angelman syndrome, but animal models suggest potential for symptom improvement at any age [6]

[Music] So I'm here to talk about taming rogue AI agents but essentially want to talk about uh evaluation driven development observability driven but really why we need observability. So, who uses AI? Is that Jim's stupid most stupid question of the day? Probably. Who trusts AI? Right. If you'd like to meet me after, I've got some snake oil you might be interested in buying. Yeah, we do not trust AI in the slightest. Now, different question. Who reads books? That's reading books. If you want some recommenda ...